BRPI0915130A2 - derivado de ácido 7h-indolo{2,1-a]{2]-benzapina-10-carboxílico para o tratamento de hepatite c - Google Patents

derivado de ácido 7h-indolo{2,1-a]{2]-benzapina-10-carboxílico para o tratamento de hepatite c

Info

Publication number
BRPI0915130A2
BRPI0915130A2 BRPI0915130A BRPI0915130A BRPI0915130A2 BR PI0915130 A2 BRPI0915130 A2 BR PI0915130A2 BR PI0915130 A BRPI0915130 A BR PI0915130A BR PI0915130 A BRPI0915130 A BR PI0915130A BR PI0915130 A2 BRPI0915130 A2 BR PI0915130A2
Authority
BR
Brazil
Prior art keywords
benzapine
indole
hepatitis
treatment
carboxylic acid
Prior art date
Application number
BRPI0915130A
Other languages
English (en)
Inventor
W. Martin Scott
P. Bergstrom Carl
Ding Min
Zheng Xiaofan
G. Gentles Robert
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40786514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0915130(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BRPI0915130A2 publication Critical patent/BRPI0915130A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0915130A 2008-05-06 2009-05-05 derivado de ácido 7h-indolo{2,1-a]{2]-benzapina-10-carboxílico para o tratamento de hepatite c BRPI0915130A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5074308P 2008-05-06 2008-05-06
PCT/US2009/042805 WO2009137454A1 (en) 2008-05-06 2009-05-05 7h-indolo[2,1-a] [2] benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
BRPI0915130A2 true BRPI0915130A2 (pt) 2019-09-24

Family

ID=40786514

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915130A BRPI0915130A2 (pt) 2008-05-06 2009-05-05 derivado de ácido 7h-indolo{2,1-a]{2]-benzapina-10-carboxílico para o tratamento de hepatite c

Country Status (19)

Country Link
US (1) US8133884B2 (pt)
EP (1) EP2280975B1 (pt)
JP (1) JP2011520810A (pt)
KR (1) KR20110015588A (pt)
CN (1) CN102083834A (pt)
AR (1) AR071684A1 (pt)
AU (1) AU2009244409A1 (pt)
BR (1) BRPI0915130A2 (pt)
CA (1) CA2723683A1 (pt)
CL (1) CL2009001089A1 (pt)
CO (1) CO6290645A2 (pt)
EA (1) EA201001748A1 (pt)
IL (1) IL208753A0 (pt)
MX (1) MX2010011921A (pt)
NZ (1) NZ588556A (pt)
PE (1) PE20091879A1 (pt)
TW (1) TW200951135A (pt)
WO (1) WO2009137454A1 (pt)
ZA (1) ZA201007649B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
CN101980711B (zh) 2008-03-27 2012-10-31 百时美施贵宝公司 芳族杂环稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2655362A1 (en) 2010-12-22 2013-10-30 Abbvie Inc. Hepatitis c inhibitors and uses thereof
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
IN2014MN01547A (pt) 2012-02-10 2015-05-08 Lupin Ltd
EP3091022A3 (en) * 2012-07-18 2016-12-14 Bristol-Myers Squibb Holdings Ireland Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CA2585084A1 (en) 2004-10-26 2006-05-04 Immacolata Conte Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) * 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
DE602007006796D1 (de) * 2006-05-25 2010-07-08 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20090018163A1 (en) * 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C

Also Published As

Publication number Publication date
CO6290645A2 (es) 2011-06-20
ZA201007649B (en) 2012-04-25
PE20091879A1 (es) 2009-12-19
TW200951135A (en) 2009-12-16
EP2280975A1 (en) 2011-02-09
WO2009137454A1 (en) 2009-11-12
MX2010011921A (es) 2010-11-30
CN102083834A (zh) 2011-06-01
NZ588556A (en) 2012-06-29
EP2280975B1 (en) 2014-01-01
AU2009244409A1 (en) 2009-11-12
EA201001748A1 (ru) 2011-06-30
CL2009001089A1 (es) 2011-04-29
AR071684A1 (es) 2010-07-07
US8133884B2 (en) 2012-03-13
JP2011520810A (ja) 2011-07-21
CA2723683A1 (en) 2009-11-12
US20090280083A1 (en) 2009-11-12
IL208753A0 (en) 2010-12-30
KR20110015588A (ko) 2011-02-16

Similar Documents

Publication Publication Date Title
CY2020032I2 (el) Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβια
CY2018030I2 (el) Φαρμακοτεχνικη μορφη 514
DK3309139T3 (da) Process for the preparation of 2,3,3,3-trifluoropropene
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
DK2300443T3 (da) Triazolderivater, der er anvendelige til behandling af sygdomme
BRPI0907563A2 (pt) Derivados de 4,5-di-hidro-xazol-2-il amina
ZA201105720B (en) Compounds for the treatment of hepatitis c
BRPI0922904A2 (pt) "compostos"
BRPI0916006A2 (pt) "lâmpada elétrica"
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
BRPI0914533A2 (pt) "métodos"
BRPI0915130A2 (pt) derivado de ácido 7h-indolo{2,1-a]{2]-benzapina-10-carboxílico para o tratamento de hepatite c
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
BRPI0908866A2 (pt) mastiques
BRPI0916395A2 (pt) compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno
DK2271321T3 (da) Farmaceutisk sammensætning 271
BRPI0912679A2 (pt) composição farmacêutica para o tratamento de fibromialgia
BRPI0914139A2 (pt) composições pediátricas para o tratamento de esclerose múltipla
BRPI0919200A2 (pt) derivado de aminoácido
IT1391108B1 (it) Processo per la preparazione di etilidennorbornene.
ITRM20080037A1 (it) Procedimento per la ultrapurificazione di alginati.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.